Pulmonx (NASDAQ:LUNG) Given New $13.00 Price Target at Piper

Pulmonx (NASDAQ:LUNG – Free Report) had its price target lowered by Piper Sandler from $17.00 to $13.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has an overweight rating on the stock. Other equities research analysts have also issued reports about the company. Citigroup increased their target price […]

Related Keywords

Hong Kong , Canada , Craig Hallum , David Aaron Lehman , Piper Sandler , Geoffrey Beran Rose , Hong Kong Ltd , Ensign Peak Advisors Inc , Pulmonx Corporation , Citigroup , Canaccord Genuity Group , Us Bancorp , Pulmonx Company Profile , Royal Bank , Securities Exchange Commission , Free Report , Genuity Group , Moderate Buy , Get Free Report , Exchange Commission , General Counsel David Aaron Lehman , Peak Advisors Inc , Kong Ltd , Zephyr Endobronchial Valve , Chartis Pulmonary Assessment System , Pulmonx Daily , Pulmonx , Nasdaq Lung , Lung , Medical , Lower Price Target ,